In continuation of my update on Regorafenib Oral multikinase inhibitor regorafenib achieves significantly improved survival r...

I n continuation of my update on  regorafenib A new targeted drug demonstrated its ability to control metastatic gastrointestinal str...

In continuation of my update on regorafenib   The experimental cancer drug regorafenib appears to extend survival slightly in pati...

Bayer HealthCare Pharmaceuticals, announced the results from its Phase III trial evaluating its investigational compound regorafenib (see ...